PHAGE4DAIR A multicenter, double-blind Phase I/II trial evaluating safety and efficacy of a fixed phage cocktail vs. placebo + DAIR in treating S. aureus prosthetic joint infections.
- Coordinator
- Qeen Biotechnologies Inc., Canada
- Runs
- 1 June 2026 to 31 May 2031
- Status
- Running
- EU funding
- €14.9m
- Total cost
- —
- Partners
- 25 organisations in 9 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101287116
What the project is doing
In the project's own words, from its summary on CORDIS.
PHAGE4DAIR: Phage therapy for Arthroplasty infections using Local and Conservative surgery (DAIR)PHAGE4DAIR is a multicenter, randomized, double-blind, placebo-controlled, adaptive Phase I/II clinical trial evaluating the safety and preliminary efficacy of a GMP-manufactured 5-phage cocktail targeting Staphylococcus aureus in prosthetic joint infections (PJI) treated using DAIR (Debridement, Antibiotics, and Implant Retention).
Acute S. aureus PJI represents approximately 23% of prosthetic hip and knee infections, with DAIR performed in over 40% of acute cases . Despite its conservative advantages, DAIR is associated with high failure rates, especially in antibiotic-resistant infections, underscoring the urgent need for novel adjunctive therapeutics. This Horizon Europe trial integrates a seamless Bayesian adaptive design to evaluate dose, route, and treatment efficacy over time.
The investigational phage cocktail is already under IND in the United States for related indications, facilitating transatlantic regulatory alignment. Patients will be enrolled based on confirmed S. aureus infection undergoing DAIR, with phages administered intraoperatively and intravenously alongside standard-of-care antibiotics. Co-primary endpoints include safety and clinical cure 3 months post-antibiotic completion.
PHAGE4DAIR will generate high-quality clinical, PK/PD, immunological, and microbiological data to support regulatory decision-making. The consortium includes leaders in GMP manufacturing, clinical trials, and regulatory science. A robust dissemination, exploitation, and regulatory strategy ensures a clear pathway to EMA Scientific Advice, stakeholder engagement, and future Phase III readiness. The project directly supports Horizon Europe’s goal to accelerate phage-based solutions for antimicrobial resistance and foster biotech innovation for difficult-to-treat infections.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Qeen Biotechnologies Inc. | Gatineau | Canada | Coordinator |
| European Hip Society | Innsbruck | Austria | Associatedpartner |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| Canadian Arthroplasty Society | Westmount | Canada | Associatedpartner |
| Ottawa Hospital Research Institute Corporation | Ottawa Ontario | Canada | Participant |
| The Governors of the University of Alberta | Edmonton | Canada | Participant |
| Unity Health Toronto | Toronto | Canada | Participant |
| University of Calgary | Calgary Alberta | Canada | Participant |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Aristotelio Panepistimio Thessalonikis | Thessaloniki | Greece | Participant |
| Centre Hospitalier Universitaire De Nice | Nice | France | Participant |
| Hospices Civils De Lyon | Lyon | France | Participant |
| Universite Lyon 1 Claude Bernard | Villeurbanne Cedex | France | Participant |
| Academisch Ziekenhuis Groningen | Groningen | Netherlands | Participant |
| Acibadem Mehmet Ali Aydinlar University | Istanbul | Türkiye | Associatedpartner |
| Bone and Joint Infection Society | London | United Kingdom | Associatedpartner |
| Centre for Process Innovation Limited Lbg | Redcar Cleveland | United Kingdom | Participant |
| Cambridge University Hospitals NHS Foundation Trust | Cambridge | United Kingdom | Participant |
| Micron Research Limited | Ely | United Kingdom | Participant |
| The Royal National Orthopaedic Hospital National Health Service Trust | Stanmore | United Kingdom | Participant |
| The University of Exeter | Exeter | United Kingdom | Participant |
| University College London | London | United Kingdom | Participant |
| University College London Hospitalsnhs Foundation Trust | London | United Kingdom | Participant |
| University Hospital Birmingham Nhs Foundation Trust | Birmingham | United Kingdom | Participant |
| Mayo Clinic | Rochester | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI